Reference

1. Nayak C, Oberai P, Varanasi R, Baig H, Ch R, Reddy GR, et al. A prospective multi centric open clinical trial of homeopathy in diabetic distal symmetric polyneuropathy. Homeopathy 2013; 102:130-8.
2.  Bykerk VP, Keystone EC, Kuriya B, Larché M, Thorne JC, Haraoui B. Achieving remission in clinical practice: lessons from clinical trial data. Clin Exp Rheumatol 2013; in press.
3. Brater DC and Walter JD. Clinical pharmacology in the Middle Ages: Principles that presage the 21st century. Clin Pharmacol Therap 2000; 67: 447-50.
4. http://clinicaltrials.gov/ct2/aboutstudies/glossary. Assessed on April 10,2013.
5. The current perspectives in clinical research: computer-assisted drug designing, ethics, and good clinical practice. Kandi V, Vundecode A, Godalwar TR, Dasari S, Vadakedath S, Godishala V. Borneo J Pharm. 2022;5:161–178.
6. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c869.
7. Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designs. Burnett T, Mozgunov P, Pallmann P, Villar SS, Wheeler GM, Jaki T. BMC Med. 2020;18:352.
8. Opportunity for efficiency in clinical development: an overview of adaptive clinical trial designs and innovative machine learning tools, with examples from the cardiovascular field. Sverdlov O, Ryeznik Y, Wong WK. Contemp Clin Trials. 2021;105:106397.
9. United States Government. Rules committee print 114-67, text of House amendment to the Senate, amendment to H.R. 34, Tsunami Warning, Education, and Research Act of 2015, 2016:162–3. 114th Congress.
10. Microbes, clinical trials, drug discovery, and vaccine development: the current perspectives. Kandi V, Suvvari TK, Vadakedath S, Godishala V. Borneo J Pharm. 2021;4:311–323.
11. Research question, objectives, and endpoints in clinical and oncological research: a comprehensive review. Purna Singh A, Shahapur PR, Vadakedath S, et al. Cureus. 2022;14:0.
12. Spieth PM, Kubasch AS, Penzlin AI, Illigens BM, Barlinn K, Siepmann T, et al. Randomized controlled trials - A matter of design. Neuropsychiatr Dis Treat. 2016;12:1341–9.
13. Clinical research: an overview of study types, designs, and their implications in the public health perspective. Kandi V, Vadakedath S. Am J Clin Med Res. 2021;9:36–42.
14. The Lancet (2009). "Phase 0 trials: A platform for drug development?". The Lancet. 374 (9685): 176–118.
15. Yang, Z. J., et al. (2010). "Motivation for Health Information Seeking and Processing About Clinical Trial Enrollment." Health Communication 25(5): 423-436.
16. Life Sciences Strategy Group, (May 2009) "Clinical Trial Technology Utilization, Purchasing Preferences & Growth Outlook" Syndicated Publication,
17. Gravetter FJ, Forzano LAB. Research Methods for the Behavioral Sciences. 3rd ed Wadsworth Cengage Learning; Belmont, CA: 2009.
18. Mapstone J, Elbourne D, Roberts I. Strategies to improve recruitment to research studies. Cochrane Database Syst Rev. 2007;(2) MR000013
19. "India: Prime Destination for Unethical Clinical Trials". Common Dreams.
20. Paul J, Seib R, Prescott T (Mar 2005). "The Internet and Clinical Trials:Background, Online Resources, Examples and Issues" (Free full text).Journal of medical Internet research. 7 (1): e5.
21. ICH Guideline for Good Clinical Practice: Consolidated Guidance
22. Ginsberg HN, Kris-Etherton P, Dennis B, Elmer PJ, Ershow A, Lefevre M, Pearson T, Roheim P, Ramakrishnan R, Reed R Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: the DELTA study, protocol 1 Arterioscler Thromb Vasc Biol, 18 (3) (1998), pp. 441-449.
23. Berglund L, Lefevre M, Ginsberg HN, Kris-Etherton PM, Elmer PJ, Stewart PW, Ershow A, Pearson TA, Dennis BH, Roheim PS Comparison of monounsaturated fat with carbohydrates as a replacement for saturated fat in subjects with a high metabolic risk profile: studies in the fasting and postprandial states.
24. Howard BV, Van Horn L, Hsia J, Manson JE, Stefanick ML, Wassertheil-Smoller S, Kuller LH, LaCroix AZ, Langer RD, Lasser NL Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial
25. Appel LJ., Champagne CM, Harsha DW, Cooper LS, Obarzanek E, Elmer PJ, Stevens VJ, Vollmer WM, Lin PH, Svetkey LP Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial.
26. Dwan K, Gamble C, Williamson PR, Kirkham JJ. Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias — An Updated Review. Boutron I, editor. PLoS ONE [Internet]. Public Library of Science (PLoS); 2013 Jul 5;8(7):e66844
27. Lexchin J. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ [Internet]. BMJ; 2003 May 29;326(7400):1167–70.
28. Hyman DM, Solit DB, Arcila ME, et al. Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials. Drug Discov Today. 2015; 20: 1422-1428.
29. Altman DG, Bland JM. How to randomise. BMJ. 1999; 319: 703-704.
30. Suresh K. An overview of randomization techniques: An unbiased assessment of outcome in clinical research. J Hum Reprod Sci. 2011; 4: 8-11.
31. Karanicolas PJ, Farrokhyar F, Bhandari M. Practical tips for surgical research: Blinding: Who, what, when, why, how? Can J Surg. 2010; 53: 345-348.
32. Lim HJ, Hoffmann RG. Study design: The basics. Methods Mol Biol. 2007; 404: 1-17.
33. Neutel JM and Smith DHG. Evaluation of angiotensin II receptor blockers for 24-hour blood pressure control: meta-analysis of a clinical database. J Clin Hypertens. 2003; 5(1): 58-63.
34. Wan M., Orlu-Gul M., Legay H., Tuleu C. Blinding in pharmacological trials: The devil is in the details. Arch. Dis. Child. 2013;98:656–659. doi: 10.1136/archdischild-2013-304037.
35. Blader J.C. Can keeping clinical trial participants blind to their study treatment adversely affect subsequent care? Contemp. Clin. Trials. 2005;26:290–299. doi: 10.1016/j.cct.2005.01.003.
36. Brown CH, Ten Have TR, Jo B, Dagne G, Wyman PA, Muthén B, Gibbons RD. Adaptive designs for randomized trials in public health. Annu Rev Public Health. 2009;30:1–25.
37. Guidance for industry: Adaptive design clinical trials for drugs and biologics. Washington DC, USA: Food and Drug Administration; 2010. Food and Drug Administration.
38. Chow SC, Chang M. Adaptive design methods in clinical trials- a review. Orphanet J Rare Dis. 2008;3:11.
39. Lowe D. What you need to know about adaptive trials.
40. An adaptive dose-finding design is often used in early-phase clinical development to identify the minimum effective dose and the maximum tolerable dose, which is used to determine the dose level for the next phase clinical trials.
41. Charkravarty A. Regulatory aspects in using surrogate markers in clinical trials. In: Burzykowski T, Molenberghs G, Buyse M, editors. The Evaluation of Surrogate Endpoint. New York: Springer; 2005.
42. Wang SJ, O’Neill RT, Hung HM. Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharm Stat. 2007;6:227–44.
43. Chang M. New York: CRC Press; 2007. Adaptive Design Theory and Implementation Using SAS and R.
44. Chow SC, Chang M. Adaptive design methods in clinical trials- a review. Orphanet J Rare Dis. 2008;3:11.
45. Hommel G. Adaptive modifications of hypotheses after an interim analysis. Biom J. 2001;43:581–9.
46. Friedman LM, Furberg CD, DeMets DL, Reboussin DM, Granger CB. Fundamentals of Clinical Trials. Switzerland: Springer; 2015.
47. Proschan MA, Lan KG, Wittes JT. Statistical Monitoring of Clinical Trials: A Unified Approach. New York, NY: Springer Science & Business Media; 2006.
48. Montori VM, Devereaux PJ, Adhikari NK, Burns KE, Eggert CH, Briel M, et al. Randomized trials stopped early for benefit: A systematic review. JAMA. 2005;294:2203–9.
49. Ioannidis JP. Contradicted and initially stronger effects in highly cited clinical research. JAMA. 2005;294:218–28.
50. Food and Drug Administration. Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics. 2010. [Last accessed on 2016 Jun 15.
51. Sinha BK. Interim Analysis in Clinical Trial, ppt. [Last accessed on 2016 Feb 21.
52. A. Ramamoorthy, M.A. Pacanowski, J. Bull, et al.Racial/ethnic differences in drug disposition and response: review of recently approved drugs.
53. The Society for Women's Health Research United States Food and Drug Administration Office of Women's Health. Dialogues on diversifying clinical trials: successful strategies for engaging women and minorities in clinical trials; 2011.
54. V.T. Covello Effective risk and crisis communication during water security emergencies: summary report of EPA sponsored message mapping workshops: National Homeland Security Research Center, Office of Research and Development, US Environmental Protection Agency